This bill, HB 1772-FN-A, establishes a framework for the state's involvement in a multistate consortium to conduct clinical trials using ibogaine as an investigational new drug for treating substance use disorders and other neurological or mental health conditions. It introduces a new chapter, Chapter 126-ZZ, which includes definitions, participation criteria, and reporting requirements, as well as the creation of two dedicated funds: the Ibogaine Clinical Research Trial Fund and the Ibogaine Intellectual Property Fund. The Department of Health and Human Services will administer a grant program to support these trials, with eligibility criteria that require entities to have a history of research in neurological diseases and a commitment to securing matching funds from non-state sources. The bill also includes a $1 appropriation for the fiscal year ending June 30, 2027, to facilitate the state's participation in the consortium.

Additionally, the bill amends existing law to incorporate provisions for the dedicated funds and outlines the conditions under which ibogaine can be prescribed and administered, contingent upon FDA approval. It mandates quarterly reports from grantees and an annual report to the Legislature, while allowing the Department to seek federal waivers before implementation. The fiscal impact includes estimated expenditures of $450,000 in FY 2027, $558,000 in FY 2028, and $584,000 in FY 2029, with the Department incurring administrative costs to manage the grant program. The bill does not create new fees or fines and allows the Department to accept federal funds, gifts, grants, and donations for the grant program.

Statutes affected:
Introduced: 6:12
HB1772 text: 6:12